Proteus Biomedical, a biomedical technology company out of Redwood City, California, was selected as one of the World Technology Forum's Technology Pioneers for 2009 in the field of intelligent medicine.
The company develops MEMS (microfabricated, multicomponent electronic components) devices for medical applications, small enough to be attached to pills to be used as "ingestible event markers", as well as potential permanently embedded blood glucose monitoring chips.
A statement by the company:
"Proteus has developed a unique approach to personalizing therapy," said Andrew Thompson, Proteus CEO and co-founder. "We embed micro-sensors into existing drugs and devices, which transmit information, securely, to a person's cell phone via the Internet. A person can understand how their body is responding to their therapy, and, if they choose, share this information with a family member, physician or friend to help them stay healthy. We are delighted that the World Economic Forum has recognized the immense potential of this approach and look forward to actively participating in their programs."
Check out this video interview with Andrew Thompson:
And, Proteus Biomedical's promotional video:
COMMENTARY: That's very cool technology that can give doctors immediate feedback about how a specific drug is performing and how the patient is reacting to that drug.
In the above video, Andrew Thompson makes one of the best "pitches" that I have heard in a long time. That's what I call a knockout pitch.
Essentially Proteus Biomedical makes "intelligent medicine" that consist of therapeutic drugs and tiny biosensors on a microchip that are implanted on a pharmaceutical drug pill that communicate with a cell phone via Bluetooth.
Proteus Biomedical's intelligent medicine integrates electronics, sensors, and wireless communications into pharmaceuticals like pills. It offers a monitoring system called Raisin Personal Monitor, a wireless health monitor for remote recording and analysis of heart rate, physical activity, body position, and patient-logged events.
The company which was founded in 2001 and is based in Redwood City, California, develops these biosensors to allow cardiac resynchronization therapy to be tailored and adjusted based on a patient’s cardiovascular physiology.
When ingested, any discrete event (such as the ingestion of a specific pharmaceutical) can be recorded. However, it also records any physiologic information such as heart rate, activity, body angle and patient-logged information. The unique ingestion event and all logged information are then communicated via Bluetooth to any computerized device, such as mobile phone applications. The system is being developed as part of an integrated intelligent medicine system to track response and outcomes-based of treatments. Proteus partners are currently developing these products to treat diabetes, cardiovascular disease, psychiatric disorders, organ transplantation and infectious disease.
Proteus is a privately-held company with financial investors including Adams Street Partners, Asset Management, The Carlyle Group, Essex Woodlands, Fletcher Spaght Ventures, L.P. (FSV), Kaiser Permanente Ventures, and Spring Ridge Ventures. That's an impressive list of investors.